Research progress and application prospects of animal models of group B Coxsackievirus infections

Emerg Microbes Infect. 2025 Dec;14(1):2441391. doi: 10.1080/22221751.2024.2441391. Epub 2024 Dec 22.

Abstract

Group B Coxsackieviruses (CVBs) consist of six serotypes, CVB1 to CVB6, which can clinically affect the heart, brain, liver, pancreas and other organs, causing myocarditis, encephalitis, myelitis, pancreatitis, hand-foot-and-mouth disease (HFMD) and other diseases, and can even lead to death. CVBs are widespread globally and highly contagious. However, there are currently no approved CVB vaccines or effective treatments. The construction and optimization of animal models will aid in the in-depth understanding of CVB infections and its pathogenesis, providing essential tools for the exploration of vaccine development and antiviral therapies. This paper reviews the latest research progress and application prospects of CVB animal models.

Keywords: Group B coxsackieviruses; animal model; infection; infectious disease; vaccine and drug research.

Publication types

  • Review

MeSH terms

  • Animals
  • Coxsackievirus Infections* / virology
  • Disease Models, Animal*
  • Enterovirus B, Human / genetics
  • Enterovirus B, Human / physiology
  • Hand, Foot and Mouth Disease / virology
  • Humans
  • Mice